HIV/AIDS Subpopulation
Value Based Payment Quality Measure Set
Measurement Year 2021
- Measure Set is also available in Portable Document Format (PDF)
February 11, 2021 NYS Medicaid Value Based Payment
INTRODUCTION
The Measurement Year (MY) 2021 HIV/AIDS Quality Measure Set was created in collaboration with the HIV/AIDS Clinical Advisory Group (CAG), and the New York State (NYS) Value Based Payment (VBP) Workgroup. The goal of this measure set is to align with measures used in the Delivery System Reform Incentive Payment (DSRIP) Program, the Quality Assurance Reporting Requirements (QARR), and the Merit-based Incentive Payment System (MIPS), where applicable. The measure set was designed to encourage providers to meet high standards of patient-centered clinical care and coordination across multiple care settings throughout the HIV population.
MEASURE SELECTION AND FEASIBILITY
During the fall of 2020, the HIV/AIDS CAG reconvened as part of the AIDS Institute´s Quality Advisory Committee and made recommendations to the State on quality measures, data collection, data reporting, and support required for providers to be successful in a VBP environment.
Beginning in June of 2017, the State initiated regular meetings of the VBP Measure Support Task Force. The goal of the Task Force is to make recommendations to the State to support and inform during the Annual Measure Review Cycle. Members of the Task Force include professionals from various Managed Care Organizations (MCOs), VBP Pilot Contractors, Clinical Subject Matter Experts, and State Agencies, along with other professionals who have experience in quality measurement and health information technology. The Task Force provides feedback to the Department of Health (DOH) on quality measure feasibility, reporting, and calculation.
Upon receiving the CAG recommendations and Task Force feedback, the State defined a final list of measures for inclusion in MY2021. For MY2021, three measures have been removed and two measures have been added, culminating in a total of thirty-eight Category 1 and 2 HIV/AIDS Quality Measures.
MEASURE CLASSIFICATION
Each measure has been designated by the State as Category 1, 2, or 3 with associated recommendations for implementation and testing for future use in VBP Arrangements. The measures below are classified by category based on an assessment of reliability, validity, and feasibility, and according to suggested method of use (either Pay for Reporting (P4R) or Pay for Performance (P4P)).
Categorizing and Prioritizing Quality Measures
CATEGORY 1
Approved quality measures that are deemed to be clinically relevant, reliable, valid, and feasible.
CATEGORY 2
Measures that are clinically relevant, valid, and reliable, but where the feasibility could be problematic. These measures were investigated during the 2017 & 2020 pilot programs.
CATEGORY 3
Measures that are insufficiently relevant, valid, reliable and/or feasible.
Category 1
Category 1 quality measures as identified by the CAGs and accepted and deemed reportable by the State are to be reported by VBP Contractors to the MCO´s. These measures are also intended to be used to determine the amount of shared savings for which VBP contractors are eligible.1 At least one Category 1 P4P measure must be included in a VBP contract.
The State classified each Category 1 measure as either P4P or P4R:
- P4P measures are intended to be used in the determination of shared savings amounts for which VBP Contractors are eligible. Measures can be included in both the determination of the target budget and in the calculation of shared savings for VBP Contractors.
- P4R measures are intended to be used by the Managed Care Organizations (MCOs) to incentivize VBP Contractors for reporting data to monitor the quality of care delivered to members under the VBP contract. Incentives for reporting will be based on timeliness, accuracy, and completeness of data. Measures can be reclassified from P4R to P4P through annual CAG and State review or as determined by the MCO and VBP Contractor.
Not all Category 1 measures will be reportable for the measurement year, as reporting on some of these measures will be phased in over the next few years. Please refer to the Value Based Payment Reporting Requirements Technical Specifications Manual (MY2021) for details as to which measures must be reported for the measurement year. This manual will be updated annually each fall, in line with the release of the final VBP measure set for the subsequent year.
Categories 2 and 3
Category 2 measures have been accepted by the State based on the agreement of clinical importance, validity, and reliability, but flagged as presenting concerns regarding implementation feasibility. Some of these measures have been further investigated in the VBP Pilots.
Measures designated as Category 3 were identified as unfeasible at this time or as presenting additional concerns including accuracy or reliability when applied to the attributed member population for an arrangement, therefore Category 3 measures are not included in the measure set.
MY 2021 HIV/AIDS QUALITY MEASURE SET
The measures and State-determined classifications provided on the following pages are recommendations for MY2021. Note that measure classification is a State recommendation and implementation is to be determined between the MCO and VBP Contractor.
Measure sets and classifications are considered dynamic and will be reviewed annually. Updates will include measure additions, deletions, recategorizations, and/or reclassifications from P4R to P4P or vice versa, based on experience with measure implementation in the prior year. In 2021, the CAGs and the VBP Workgroup will re-evaluate measures and provide recommendations for MY2022. Please see Appendix A for a full list of these changes.
Note: Additional changes may have been made to the names for some of the measures presented below to ensure alignment with the naming conventions used by the official measure steward. There have not been any changes to the measure specifications associated with these name changes.
Category 1
The table below displays the Category 1 HIV/AIDS Quality Measure Set, arranged alphabetically, and includes measure title, measure steward, the National Quality Forum (NQF) number and/ or other measure identifier (where applicable), and State-recommended classification for measure use. The measure set is redlined to highlight changes made between MY2020 and MY2021. Additions are made in red text while deletions or recategorizations are made with a strikethrough.
| HIV/AIDS Measure | Measure Steward | Measure Identifier | Classification |
|---|---|---|---|
| Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder | Centers for Medicare & Medicaid Services (CMS) | NQF 1880 | P4P |
| Antidepressant Medication Management - Effective Acute Phase Treatment & Effective Continuation Phase Treatment | National Committee for Quality Assurance (NCQA) | NQF 0105 | P4P |
| Asthma Medication Ratio | NCQA | NQF 1800 | P4P |
| Breast Cancer Screening | NCQA | NQF 2372 | P4P |
| Cervical Cancer Screening | NCQA | NQF 0032 | P4P |
| Colorectal Cancer Screening | NCQA | NQF 0034 | P4P |
| Comprehensive Diabetes Care: Eye Exam (retinal) Performed | NCQA | NQF 0055 | P4P |
| Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%) | NCQA | NQF 0059 | P4P |
| Controlling High Blood Pressure | NCQA | NQF 0018 | P4P |
| Depression Remission or Response for Adolescents and Adults | NCQA | P4P | |
| Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)^^ | NCQA | P4R | |
| Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications | NCQA | NQF 1932 | P4P |
| HIV Viral Load Suppression | Health Resources and Services Administration (HRSA) | NQF 2082 | P4P |
| Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment | NCQA | NQF 0004 | P4P |
| Initiation of Pharmacotherapy upon New Episode of Opioid Dependence | NYS | - | P4P |
| Kidney Health Evaluation for Patients With Diabetes (KED)^^ | NCQA | P4P | |
| Potentially Avoidable Complications in Patients with HIV/AIDS | Altarum Institute | - | P4R |
| Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan | CMS | NQF 0421 | P4R |
| Preventive Care and Screening: Influenza Immunization | American Medical Association Physician Consortium for Performance Improvement (AMA PCPI) | NQF 0041 | P4R |
| Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention | AMA PCPI | NQF 0028 | P4R |
| Sexually Transmitted Infections: Screening for Chlamydia, Gonorrhea, and Syphilis | NYS | - | P4R |
| Statin Therapy for Patients with Cardiovascular Disease | NCQA | - | P4R |
| Use of Pharmacotherapy for Alcohol Abuse or Dependence | NYS | - | P4R |
| Use of Spirometry Testing in the Assessment and Diagnosis of COPD | NCQA | NQF 0577 | P4R |
* Measure removed from HEDIS 2021 Measure Set
** Measure specifications revised by NCQA for 2021 HEDIS Measure set
^^ Measure replaced by NCQA/HEDIS measure
^^ Replacement HEDIS measure – first year measure
Category 2
The table below displays the Category 2 HIV/AIDS Quality Measure Set and includes measure title, measure steward, and the NQF number and/or another measure identifier (where applicable). All Category 2 measures are classified as P4R in MY2021. There are no CAT2 changes between MY2020 and MY2021.
| HIV/AIDS Measure | Measure Steward | Measure Identifier |
|---|---|---|
| Asthma Action Plan | American Academy of Allergy, Asthma & Immunology (AAAAI) | - |
| Asthma: Assessment of Asthma Control – Ambulatory Care Setting | AAAAI | - |
| Asthma: Spirometry Evaluation | AAAAI | - |
| Continuing Engagement in Treatment Alcohol and Other Drug Dependence | NYS | - |
| Continuity of Care from Inpatient Detox to Lower Level of Care | NYS | - |
| Continuity of Care from Inpatient Rehabilitation for Alcohol and Other Drug Abuse or Dependence Treatment to Lower Level of Care | NYS | - |
| Diabetes Screening | NYS | - |
| Hepatitis C Screening | HRSA | - |
| Housing Status | HRSA | - |
| Linkage to HIV Medical Care | NYS | - |
| Medical Case Management: Care Plan | HRSA | - |
| Prescription of HIV Antiretroviral Therapy | HRSA | NQF 2083 |
| Sexual History Taking: Anal, Oral, and Genital (HIV/AIDS) | NYS | - |
| Substance Abuse Screening | HRSA | - |
| Use of Opioid Dependence Pharmacotherapy | NYS | - |
Appendix A
The tables below identify the changes to the Category 1 and Category 2 measures for the MY2021 HIV/AIDS Quality Measure Set.
CATEGORY 1 MEASURE CHANGES FROM 2020 TO 2021
| Measure Name | Change | Rationale for Change |
|---|---|---|
| Comprehensive Diabetes Care: Medical Attention for Nephropathy | Removed | Measure removed from HEDIS 2021 Measure Set |
| Depression Screening and Follow-Up for Adolescents and Adults (DSF-E) | Added | Replacement HEDIS measure – first year measure |
| Kidney Health Evaluation for Patients With Diabetes (KED) | Added | Replacement HEDIS measure – first year measure |
| Medication Management for People with Asthma | Removed | Measure removed from HEDIS 2021 Measure Set |
| Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan | Removed | Replaced measure with HEDIS 2021 measure |
__________________________________________________________
1. New York State Department of Health, Medicaid Redesign Team, A Path Toward Value Based Payment: Annual Update, September 2020. (Link) 1
Follow Us